

Fracture risk following intermission of osteoporosis therapy

EM Dennison, C Cooper, J A Kanis, O Bruyère, S Silverman, E McCloskey, B Abrahamsen, D Prieto-Alhambra, S Ferrari¹

EM Dennison MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom

C Cooper MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom *and* Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Kanis JA Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK University of Sheffield Medical School, United Kingdom *and* Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia

O Bruyère World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

S Silverman Cedars-Sinai/UCLA Medical Center and OMC Clinical Research Center, Beverly Hills, CA, USA

E McCloskey Academic Unit of Bone Metabolism, Department of Oncology and Metabolism, The Mellanby Centre For Bone Research, University of Sheffield, Sheffield, United Kingdom

B Abrahamsen, Department of Medicine, Holbaek Hospital, Holbaek, Denmark and OPEN, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

¹ On behalf of the IOF Epidemiology/ Quality of Life Working Group

D Prieto-Alhambra Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom and GREMPAL Research Group, Idiap Jordi Gol and CIBERFes, Universitat Autònoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Spain

SL Ferrari, Division of Bone Disease, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland

We are grateful to the Committee of Scientific Advisors of the International Osteoporosis Foundation for their review and endorsement of this paper

Correspondence to Professor Cyrus Cooper, MRC Lifecourse Epidemiology Unit, Southampton SO16 6YD, UK email cc@mrc.soton.ac.uk

Abstract

Summary Given the widespread practice of recommending drug holidays we reviewed the impact of medication discontinuation of two common anti-osteoporosis therapies (bisphosphonates and denosumab). Trial evidence suggests the risk of new clinical fractures and vertebral fracture increases when osteoporosis treatment with bisphosphonates or denosumab is stopped.

Introduction The aim of this paper was to review the available literature to assess what evidence exists to inform clinical decision making with regard to drug holidays following treatment with bisphosphonates (BiP) or denosumab.

Methods Systematic review.

Results Differing pharmacokinetics lead to varying outcomes on stopping therapy. Prospective and retrospective analyses report that the risk of new clinical fractures was 20-40% higher in subjects who stopped BiP treatment and vertebral fracture risk was approximately doubled. Rapid bone loss has been well described following denosumab discontinuation with an incidence of multiple vertebral fractures around 5%. Studies have not identified risk factors for fracture after stopping treatment other than those that provide an indication for treatment (e.g. prior fracture and low BMD). Studies that considered long-term continuation did not identify increased fracture risk, and reported only very low rates of adverse skeletal events such as atypical femoral fracture.

Conclusions The view that patients on long-term treatment with bisphosphonates or denosumab should always be offered a drug holiday is not supported by the existing evidence. Different pharmacokinetic properties for different therapies require different strategies to manage drug intermission. In contrast, long-term treatment with anti-resorptives is not associated with increased risk of fragility fractures and skeletal adverse events remain rare.

Keywords Atypical fracture · Bisphosphonates · Denosumab · Drug holiday

Introduction

The burden of osteoporotic fracture is very high, with an estimated 8.9 million fractures annually [1]. Many anti-osteoporosis medications (AOMs) are available, with the oral bisphosphonates (BP) being amongst the most widely prescribed. The efficacy of these is well established, with fracture reduction of the order of 50% possible [2]. These effects on fracture risk are offset by poor adherence to AOM, as with other therapy for long term conditions, estimated at about 35% at one year [3], although other studies suggest higher persistence for secondary fracture prevention [4]. Adherence with AOM has been further challenged in recent years with widespread publicity about rare risks associated with long term bisphosphonate use, namely atypical femoral fracture (AFF) and osteonecrosis of the jaw [5]. The recognition of these rare side events has led to the common practice of 'drug holidays' whereby patients who have been on BiP for 3-5 years are considered for their suitability for a rest from treatment, typically for 1-2 years [5-9]. Patients may be aware, through media communication, of adverse events that have been linked to long-term bisphosphonate use, and may appropriately wish to be involved about decisions regarding their osteoporosis management; patient preference, after appropriate counselling, is an important element of the osteoporosis consultation. More temperate guidance has recently been published to assist physicians in the form of guidelines from the American Society of Bone and Mineral Research and UK National Osteoporosis Guideline Group [10-11]. However, there is a growing concern that 'drug holidays' are becoming the norm in many countries, and even in high risk patients who might derive more benefit than harm from ongoing therapy, cessation of treatment is being offered [5], for example in the UK, particularly since NICE guidelines recommended stopping treatment at 3 years [12].

The aim of this work was to review the available literature to assess what evidence exists to inform clinical decision making, and to identify any clinical indicators that might inform a decision regarding whether to continue or discontinue therapy. With the advent of widespread denosumab use, we included a review of evidence for effects of stopping this therapy. This piece of work follows on from a previous editorial [5] and formed the introduction for an International Osteoporosis Foundation (IOF) project that aimed to identify surrogate markers that predict outcomes upon intermission of therapy and to develop a new algorithm based on a patient's risk profile. The four key questions we sought answers for in

the available literature were as follows: does fracture risk increase upon treatment discontinuation? Conversely, does fracture rate decrease, or remain stable upon treatment continuation? Are there patient or treatment characteristics that are associated with increase fracture risk upon discontinuation? Finally, do adverse events increase with long term exposure?

Methods

A single reviewer searched Pubmed; EMBASE; Cochrane Library; NHS Evidence; Epistemonikos; NIH records on ClinicalTrials.gov. using the following PICO criteria;

Participants - Post-menopausal women on osteoporosis medication for ≥ 1 years;

Intervention - medications for osteoporosis with focus on denosumab, or bisphosphonates/diphosphonates specifically alendronate/alendronic acid, risedronate/risedronic acid, ibandronate/ibandronic acid and zoledronate/zoledronic acid);

Comparison - Medication continuation vs discontinuation. Hormone Replacement Therapy was excluded from this systematic review.

Outcomes - Bone turnover markers; bone mineral density (BMD); fracture; osteonecrosis of the jaw; atypical femoral fracture.

Exclusion criteria were other metabolic bone diseases, non-English language guidelines, recommendations, systematic reviews, overviews and clinical opinions. However, non-English language primary research articles with English abstracts were included if relevant. We considered RCTs and observational studies, and used the following search terms: (osteoporosis OR osteopenia) AND (denosumab OR bisphosphonates [specifically alendronate/alendronic acid, risedronate/risedronic acid, ibandronate/ibandronic acid and zoledronate/zoledronic acid] OR oral treatments). We considered studies reported over the period 2011-2016, though other key literature (e.g. results from the FLEX study) were reviewed as part of this work and specifically recent studies that consider the effects of denosumab discontinuation will be discussed. Current conference abstracts (2017-2018) were considered for inclusion only if they provided essential new information to what was published in peer reviewed form.

Results

Effects of treatment discontinuation vs continuation on fracture risk (RCT data)

We identified thirty-eight articles that reported the findings of clinical trials (13 -51). The breakdown of studies was as shown in figure 1. A large number of systematic reviews (sixteen) were identified as addressing treatments, specifically bisphosphonates (namely alendronate, risedronate, ibandronate, zoledronate), or denosumab, for post-menopausal osteoporosis or osteoporosis in general. Hence, a considerable number of review papers were also identified, although the number of source trials was much less. Of the clinical trials identified for this review, the majority were extension studies of randomised controlled trials (RCTs). Some of the best data come from studies of bisphosphonates; articles reported studies including the Fracture Interventional Trial Long Term Extension (FLEX) [29,30,37,38], and the Vertebral Efficacy with Risedronate Therapy (VERT) extension studies [24]. Finally, the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial (HORIZON-PFT) extension studies have reported effect of discontinuation of bisphosphonates in some detail [14-16; 22-23].

Randomised controlled trials of osteoporosis treatment discontinuation have been undertaken. Black and colleagues compared the effects of 3 versus 6 years zoledronic acid in the HORIZON Pivotal Study [14], and found that, whilst femoral neck bone mineral density (BMD) remained constant in women randomised to 6 years of intravenous BiP, it decreased slightly in those randomised to placebo after 3 years (between treatment difference 1.04%, $p=0.0009$) with similar effects at other sites. Biochemical markers tended to rise in those allocated to placebo but remained below pre-treatment levels, and new morphometric vertebral fractures increased about two-fold after zoledronate was stopped at 3 years as compared to women maintained 6 years on therapy (OR 0.51 for 6 versus 3 years; $p=0.035$). However, no rise in risk of non-vertebral fractures was observed among those who went on placebo after 3 years compared to those who continued therapy for 6 years, although firm conclusions cannot be drawn due to limited power in this sample. A randomised second extension provided data regarding 9 years versus 6 years of treatment [16]. From year 6 to 9, the mean change in total hip BMD was -1.31% versus -0.54% in those randomised to placebo

after 6 years of treatment compared to those who continued to receive infusions (difference 0.78%; 95% confidence interval [CI]: -0.37%, 1.93%; $p = 0.183$). Bone turnover markers showed small, non-significant increases in those who discontinued after 6 years compared with those who continued for 9 years. The number of fractures was low and did not significantly differ by treatment. There was a small increase in cardiac arrhythmias (combined serious and non-serious) in the continued treatment group but no significant imbalance in other safety parameters. The results suggest almost all patients who have received six annual zoledronate infusions can stop medication for up to 3 years without apparent adverse consequences.

The implications of discontinuing alendronate treatment were considered in the FLEX study [37, 38]. This study randomized postmenopausal women aged 61 to 86 years previously treated with 4 to 5 years of alendronate therapy to 5 more years of alendronate or placebo. Among the women who had prior alendronate therapy in FIT, further therapy with alendronate (5 and 10 mg groups combined) for 3 years compared with placebo-maintained BMD at the hip (2.0% difference; 95% CI, 1.6-2.5%) and further increased BMD at the spine (2.5% difference; 95% CI, 1.9-3.1%). When comparing fracture-risk outcomes after 5 years, clinically recognized vertebral fractures were significantly more common among those discontinuing alendronate, but the cumulative risk for non-vertebral fractures and morphometric vertebral fractures were similar [38]. Given, however that alendronate did not decrease the risk of non-vertebral fracture in the overall study population (but only those with low BMD at baseline), it is not surprising that stopping treatment had no effect on the fracture outcome. Eastell et al undertook an analysis of women who had participated in the VERT-MN study, and who had received either 2 or 7 years of risedronate [24]. They report that one year of risedronate discontinuation resulted in increases of NTX/Cr levels towards baseline and decreases in femoral trochanter and total hip BMD. No fracture data were reported. In other work considering change in bone turnover markers on discontinuing bisphosphonate study, persistent reduction in bone turnover 2 years after stopping alendronate, risedronate and ibandronate was demonstrated [51].

Denosumab has been shown to be effective in improving BMD and reducing fracture among women who received up to 10 years of treatment [25, 34,47]; in the long-term treatment group, BMD increased from FREEDOM baseline by 21.7% at the lumbar spine, 9.2% at total

hip, 9.0% at femoral neck, and 2.7% at the one-third radius. The yearly incidence of new vertebral fractures (ranging from 0.90% to 1.86%) and non-vertebral fractures (ranging from 0.84% to 2.55%) remained low during the extension, similar to rates observed in the denosumab group during the first three years of the FREEDOM study, and lower than rates projected for a virtual long-term placebo cohort [46]. However, several studies have suggested that denosumab withdrawal is associated with adverse outcomes, including accelerated bone loss and vertebral fractures [39 -46]. In a first analysis of 797 subjects withdrawing from the study drug (placebo or denosumab) during the original FREEDOM study, 42% versus 28% of placebo- and denosumab-treated subjects, respectively, initiated another therapy (mostly bisphosphonates). Following discontinuation, similar percentages of subjects in both groups sustained a new fracture (9% placebo, 7% denosumab), resulting in a fracture rate per 100 subject-years of 13.5 for placebo and 9.7 for denosumab (hazard ratio [HR] 0.82; 95% confidence interval [CI], 0.49-1.38), and for vertebral fractures of 9.3 and 5.6 for off placebo and off denosumab, respectively adjusted for age and total hip BMD T-score at baseline [21]. However a more recent analysis of subjects stopping denosumab during Freedom and its extension indicates an increased risk of new or worsening vertebral fractures, though fracture risk never exceeded that in the placebo group (see below).

Risk factors for fractures upon treatment discontinuation

A number of studies have considered whether certain risk factors are associated with increased risk of fracture after discontinuation of treatment. Cosman and colleagues considered this issue with zoledronate treatment [22], and reported that after three years of treatment, those women who might benefit from continued treatment with regard to lower subsequent fracture risk were those who had a total hip T score below -2.5 or an incident fracture during the first 3 years of treatment. Other investigators have considered the factors associated with outcome after stopping alendronate treatment. For example, Schwartz and colleagues considered which groups of women might benefit from continued alendronate therapy and reported that continuing alendronate for 10 years instead of stopping after 5 years reduces non-vertebral fracture risk in women without prevalent vertebral fracture whose femoral neck T scores, achieved after 5 years of alendronate therapy, are -2.5 or less [48]. Conversely, in another analysis of the FLEX data, Bauer and colleagues [49] reported a clinical fracture incidence near 30% in the 5 years of receiving placebo after receiving 5 years

of alendronate among subjects with hip T-scores below -2.5, whereas this risk was lower than 10% in those with T-scores at -1.5 or better. McNabb et al used the FLEX data to model likely outcomes on alendronate discontinuation [29]. They reported that using their tool, in women with a total hip T score greater than -1.9 at the time of alendronate discontinuation would have less than a 20% probability of BMD dropping to below -2.5 over 5 years of follow up. However, in a separate analysis [30], the same group used the same data and reported that 5-year bone losses of >5% were experienced by 29% subjects at the total hip, 11% at the femoral neck and 1.3% at the lumbar spine. While several risk factors such as age and BMI were associated with greater bone loss, no models based on these risk factors predicted bone loss rates, reinforcing the need for caution and monitoring when considering drug intermission. In another analysis of the FLEX data, Bauer and colleagues [49] reported that while one-year changes in hip DXA, NTX, and BAP were not related to subsequent fracture risk, whereas older age and lower hip T-score at time of discontinuation were significantly related to increased fracture risk (lowest tertile of baseline femoral neck DXA versus other 2 tertiles relative hazard ratio, 2.17 [95% CI, 1.38-3.41]; total hip DXA relative hazard ratio, 1.87 [95% CI, 1.20-2.92]). Hence it appears that the main predictors of fracture on treatment discontinuation are BMD and prior fracture, i.e. similar to determinants of fracture prediction in treatment naïve patients.

In the FREEDOM extension trial, the risk of multiple vertebral fractures upon discontinuation after three years of denosumab was more than 3-fold higher among those with a prevalent vertebral fracture (incidence 5.9%, compared to 4.1% off placebo in this high risk group). The risk also increased with the duration off therapy, the gain in hip BMD on therapy, and the loss of hip BMD off therapy [50], possibly reflecting association between fracture risk and BMD. The overriding conclusion is that these studies have not identified risk factors for fracture after stopping treatment other than those that provide an indication for treatment (e.g. prior fracture and low BMD).

Observational studies

A recent observational study [77] that utilised 4 Kaiser Permanente integrated health system regions, and included 39,502 women aged ≥ 45 years with ≥ 3 years exposure to BP compared

women on a drug holiday to those with persistent BiP use. Compared to the persistent use group, there was a slight reduction in overall osteoporosis-related fracture risk (HR 0.92, 95% CI 0.84- 0.99) and no difference in hip fracture risk (HR 0.95, 95% CI 0.83-1.10) for the BP holiday group. A slight reduction in risk of vertebral fracture was also observed (HR 0.83, 95% CI 0.74-0.95). Furthermore, compared to the persistent user group, the BiP holiday group was at decreased risk for osteoporosis-related fractures (HR 0.71, 95% CI 0.65-0.79), vertebral fractures (HR 0.68, 95% CI 0.59-0.78), and hip fractures (HR 0.59; 95% CI 0.50-0.70). This seemingly unexpected result may reflect a decision by clinicians and their patients to continue therapy in those at higher risk of fracture. By contrast, an analysis of Medicare data covering 160,369 women who had been established on BP for 3 years with high refill compliance reached a different conclusion. Overall during a median follow-up of 2.7 years, those whose treatment was interrupted – suggesting implementation of a drug holiday – exhibited a significantly increased risk of hip fractures (adjusted HR of 1.22; 95% CI 1.11-1.34). The risk gradually increased with longer drug holidays and was 1.8 fold increased after a drug holiday of four years, compared with continued use [78].

Some observational studies also inform about additional risk factors for fractures upon treatment discontinuation. For example, Strom and colleagues reported that, using the Swedish Prescribed Drug Register, time on BiP treatment was inversely associated with the incidence of hospitalized fractures during post treatment follow-up [52]. In their study adjusted regression results showed that patients persisting with therapy for >12 months had 60% lower fracture risk the first six months after treatment discontinuation (RR 0.40, $p = 0.001$) compared with patients who had discontinued treatment within the first year. Of note patient characteristics, including prevalent fractures and co-morbidities, and posttreatment mortality were comparable across persistence durations, with no evidence of a healthy adherer effect. In another analysis by Xu et al, of 208 patients significant predictors of BMD decline during the BiP holiday included lower body mass index at the start of the holiday and change in body weight during the holiday [53]. BMD decline was more pronounced in former risedronate compared to former alendronate users. BMD trends were similar in patients who sustained a fracture during the holiday versus those who did not sustain [54,55].

Risks observed in long-term exposure to anti-resorptives: Atypical femoral fracture

The relationship between adverse events and treatment continuation and cessation has been considered in trials and other study designs. In HORIZON, significantly more women receiving 6 years of zoledronate treatment had transient rises in creatinine than those receiving 3 years of treatment [15] (0.65% vs 2.94%); there were non-significant differences in rates of AF and stroke in the two groups, but hypertension rates were lower in women receiving extended therapy. Adverse events profiles were not different between women who continued or discontinued risedronate [24] whilst histomorphometric studies of alendronate suggest that prolonged reduction in bone turnover is unlikely to be associated with adverse effects on bone material properties [26]. Black and colleagues performed secondary analyses using the results of three large, randomized BiP trials: the Fracture Intervention Trial (FIT), the FIT Long-Term Extension (FLEX) trial, and the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial (PFT) [56]. A total of 284 records for hip or femur fractures among 14,195 women were reviewed and 2 fractures in 10 patients classified as occurring in the subtrochanteric or diaphyseal femur, a combined rate of 2.3 per 10,000 patient-years. As compared with placebo, the relative hazard was 1.03 (95% confidence interval [CI], 0.06 to 16.46) for alendronate use in the FIT trial, 1.50 (95% CI, 0.25 to 9.00) for zoledronic acid use in the HORIZON-PFT trial, and 1.33 (95% CI, 0.12 to 14.67) for continued alendronate use in the FLEX trial. Hence in this analysis the occurrence of fracture of the subtrochanteric or diaphyseal femur was very rare, even among women who had been treated with BiPs for as long as 10 years, but the study was underpowered for definitive conclusions. However, it is important to note that without reviewing radiographs, it may be hard to definitely classify a femoral fracture as typical or atypical.

Schilcher and colleagues reviewed radiographs of Swedish women who sustained a hip fracture in 2008, identifying 59 atypical femoral fractures [57]. Data on medications and coexisting conditions were obtained from national registries. The relative and absolute risk of atypical fractures associated with BiP use was estimated by means of a nationwide cohort analysis. The 59 case patients were also compared with 263 control patients who had ordinary subtrochanteric or shaft fractures. In this study, the age-adjusted relative risk of atypical fracture was 47.3 (95% confidence interval [CI], 25.6 to 87.3) in the cohort analysis. The increase in absolute risk was 5 cases per 10,000 patient-years (95% CI, 4 to 7). A total of 78%

of the case patients and 10% of the controls had received BiPs, corresponding to a multivariable-adjusted odds ratio of 33.3 (95% CI, 14.3 to 77.8). The duration of use influenced the risk (odds ratio per 100 daily doses, 1.3; 95% CI, 1.1 to 1.6). Importantly after drug withdrawal, the risk diminished by 70% per year since the last use (odds ratio, 0.28; 95% CI, 0.21 to 0.38). In a follow-up paper of 172 patients with atypical femoral fractures the age-adjusted relative risk (RR) of atypical fracture associated with BiP use was 55 (95% CI: 39-79) in women and 54 (CI: 15-192) in men (58). In BiP users, women had a 3-fold higher risk than men (RR = 3.1, CI: 1.1-8.4). Alendronate users had higher risk than risedronate users (RR = 1.9, CI: 1.1-3.3). The RR after 4 years or more of use reached 126 (CI: 55-288), with a corresponding absolute risk of 11 (CI: 7-14) fractures per 10,000 person-years of use. The risk decreased by 70% per year since last use. These data are complementary to previously reported figures that suggest the incidence of atypical femoral fracture appears related to duration of exposure. This observation receives some support from preliminary reports from the Southern California Osteoporosis Cohort Study (SOCS) where the risk of radiology adjudicated AFFs declined by 44% in the first year after discontinuation compared to women who continued to use BiPs (HR 0.56, CI 0.38-0.82). After 4 years or more, the AFF risk was found to be reduced by 78% (HR 0.22, CI 0.08-0.59) compared to current users. The rate of AFFs among current users was reported as 4.6 per 10,000 patient years [59].

Dell using radiographic review of claims data found a rate of AFF of 2/100,000 after 2 years exposure and 78/100,000 after 8 years of exposure [60]. Finally a recent systematic review [61] included twenty-three studies on atypical femoral fractures: 14 on epidemiology and 11 on treatment outcomes (two articles reported on both aspects). The review showed that the incidence of atypical femoral fractures is low (3.0-9.8 per 100,000 person-years) but relative risk increased with longer duration of BiP use, especially after more than three years; it also suggested that female sex, and Asian ethnicity may be risk factors for the condition, in addition to reporting post-operative outcomes (often poor). The high mortality following these fractures has also been reported [62].

What about osteonecrosis of the jaw with long-term bisphosphonates?

Osteonecrosis of the jaw (ONJ) is a very rare clinical event that was first reported in connection with bisphosphonate use in 2003 [63]. The incidence of ONJ is rare and increases with exposure; an inflection point of 4 years has been suggested [63]. The AAOMS using data from Lo [64] estimated 210/100,000 patient years. The American Society for Bone and Mineral Research (ASBMR) estimated ONJ incidence as between 1 in 10,000-100,000 patient-treatment years [65]. Most of the reported cases have been in association with the use of zoledronate or pamidronate used intravenously to control metastatic bone disease [63, 67-68]. The risk of ONJ in association with the use of oral BiPs is very much less, and was reviewed by Masoodi in 2009, who concluded that the use of oral BiPs did not increase the risk of ONJ in osteoporosis patients [68]. Furthermore, no cases of ONJ were reported in over 3000 patients participating in clinical studies of effectiveness of alendronate and zoledronate [38,68]. More recent studies have suggested that pre-existing dental disease and prior dental extraction are the strongest risk factors [69,70]. Danish national health data also suggest a low incidence rate of surgically treated ONJ of 2.5 (95% confidence interval 2.1 to 3.1) per 10,000 patient years for users of oral BiPs, albeit a higher risk in users with 5 years of exposure or more. The risk was higher in patient with rheumatoid disorders or diabetes [71]. Denosumab therapy has also been associated with ONJ. The incidence of adverse and serious adverse events did not increase over time in the denosumab extension study; through extension year 5, eight events of osteonecrosis of the jaw and two events of atypical femoral fracture were confirmed [34]. Very recently, 10-year data have been published for denosumab therapy [47]. Serious adverse event rates were generally stable over time, varying between 11.5 and 14.4 per 100 participant-years, against a backdrop of 10.9 to 11.7 per 100 participant-years in placebo. One atypical femoral fracture occurred in each group during the extension. Seven cases of osteonecrosis of the jaw were reported in the long-term group and six cases in the crossover group.

Discussion

This review served to consider the amount and quality of information relating to effects of discontinuing or continuing BiPs or denosumab therapy in osteoporotic women. In recent publications, the effect of discontinuation of denosumab on BMD and vertebral fractures has been highlighted [39-46], and it is now recognised that in some patients, this is associated

with multiple vertebral fractures, although identification of those at risk is problematic (other than previous fracture). In general, the risks associated with interrupting osteoporosis therapy, including with BiPs, is poorly appreciated, particularly because a large proportion of treated subjects may remain at high fracture risk even after five years of therapy, and there is a need to highlight this among patients and primary care physicians. Interrupting treatment may be justified, in the case of BiPs, given certain treatment goals have been met but the decision should always be taken in consultation with the patient, after considering the full spectrum of clinical risk factors which determines the risk of recurring fragility fractures, [11].

These observations have led to a number of position papers and guidelines [9-13], which generally reinforce the importance of continuing therapy among women who remain at high risk of fracture, as intermission of therapy, even those with residual effects on bone turnover after intermission, such as BiPs, will be followed by an increase in fracture incidence in those subjects. Despite these recommendations, more than 1 in every two patient stops therapy after two years and most physicians would stop therapy regardless of risk evaluation after 3 to 5 years. When considering long-term therapy though, one has to balance benefits and risks. With the exception of denosumab, the number of patients in RCTs carried through to ten years or longer is very small. A particular concern of patients and physicians alike is the apparent association of osteoporosis treatment with atypical femoral fractures and ONJ. However, this risk remains less than 1 in 1000 subjects treated even for 10 years according to most long-term extensions of RCTs and observational studies. Although the long-term benefits remain difficult to exactly evaluate in absence of large placebo-controlled extension studies, assuming a long-term reduction of fracture risk in the order of 30% with anti-resorptive therapy, as suggested by the available evidence, particularly among high risk subjects, would result in a benefit: risk ratio (fractures prevented: adverse skeletal event) of at least 100:1. Observational data suggest that patients treated with oral bisphosphonates in excess of ten dose years maintain a low incidence of both hip fractures and fractures of the subtrochanteric femur and femoral shaft [72].

While many observational studies were reviewed as part of this exercise, in general they were unable to add significantly to the evidence base, as they lead to variable, and sometimes contradicting observations regarding fracture risk after treatment with bisphosphonates is discontinued. Some of these studies considered factors associated with BiP treatment failure;

these included smoking, baseline alkaline phosphatase, spinal deformity, baseline lumbar spine BMD [76]. Of note, observational data are always vulnerable to confounding by indication; women who chose to remain on treatment, and who are encouraged by physicians to do so, differ in many ways related to fracture risk to those who do not, and it is difficult to disentangle competing risks. Based on the most recent studies from the United States [58,76], which are observational and which have not yet been published in peer reviewed form, a drug holiday for one year in 10,000 women should avoid two AFFs but would be associated with 25 additional hip fractures due to the much higher rate of hip fractures over AFFs. As discussed above, this would also come accompanied by additional non-hip major osteoporotic fractures. Hence this supports the concept that a drug holiday, even with BiPs, should be considered only in patients at low risk of fracture.

In conclusion, the available evidence from prospective and retrospective analyses indicates that treatment cessation is often associated with an increase in fracture risk. From the randomised trial data available, it appears that the strongest predictor of outcome after interrupting therapy are age and BMD at discontinuation. Women whose hip T score is below -2.5 or even in the osteopenic range after 3 years, have prevalent fragility fractures, are older, and/or were poorly compliant with therapy, are at highest risk for new fractures and should therefore receive continued therapy for osteoporosis. The difference in pharmacokinetics between the BiPs and denosumab is a very important distinction that must be clearly communicated to primary care physicians and patients commenced on this therapy. An important limitation of this review is the lack of clinical trial data from which we can infer best practice; further studies to inform algorithm development are now warranted, particularly in subgroups where available data are very limited, such as male osteoporosis, steroid induced osteoporosis and populations of different ethnicities.

Acknowledgements

This study was supported by an unrestricted grant from MSD. The sponsor did not have any role in preparation, review or approval of the manuscript. The initial systematic review was performed by Nadia Corp. We are grateful to the Committee of Scientific Advisors of the International Osteoporosis Foundation for their review and endorsement of this paper.

Competing Interests

JAK reports grants from Amgen, Eli Lilly and Radius Health; non-financial support from Medimaps, and Asahi; and other support from AgNovos. JAK is the architect of FRAX but has no financial interest. CC reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. OB reports research grants from Biophytis, IBSA, MEDA, Servier and SMB outside the submitted work. DPA reports grants from Amgen, Servier, and UCB, and departmental fees for speaker or consultancy services from Amgen and UCB. BA declares research grants from Novartis and UCB, speaker fees from Amgen and consulting and speaker fees from UCB. SF reports consulting and/or speaker honoraria from Amgen, UCB, Lilly, Labatec, AgNovos, Pfizer. EM reports Consultant/Advisor/Speaker fees from ActiveSignal, AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, GSK, Hologic, Internis, Lilly, Medtronic, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, Tethys, UCB, Warner Chilcott, research support from ActiveSignal, AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, GSK, Hologic, Internis, Lilly, Medtronic, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, Tethys, UCB, Warner Chilcott, ARUK, I3 Innovus, MRC, IOF, Unilever. ED reports consulting and speaker fees from Pfizer and UCB.

References

1. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 17(12):1726-33. <https://doi.org/10.1007/s00198-006-0172-4>
2. Lindsay R, Watts NB, Lange JL, Delmas PD, Silverman SL (2013). Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. *Osteoporos Int* 24(8):2345-2352. <https://doi.org/10.1007/s00198-006-0274-z>
3. Reyes C, Tebe C, Martinez-Laguna D, Ali MS, Soria-Castro A, Carbonell C, Prieto-Alhambra D (2017) One and two year persistence with different anti-osteoporosis medications: a retrospective cohort study. *Osteoporos Int* 28(10):2997-3004. <https://doi.org/10.1007/s00198-017-4144-7>
4. Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: A nationwide analysis of prescription rates and persistence. *Osteoporos Int* 20(2):299-307. <https://doi.org/10.1007/s00198-008-0651-x>
5. Silverman SL, Adachi JD, Dennison E, et al. (2016) Bisphosphonate drug holidays: we reap what we sow. *Osteoporos Int*. 27(3):849-852. <https://doi.org/10.1007/s00198-015-3453-y>
6. Whittaker M, Guo J, Kehoe T et al (2012) Bisphosphonates for osteoporosis – where do we go from here? *N Engl J Med* 366; 2048-51. <https://doi.org/10.1056/NEJMp1202619>
7. Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Perez-Lopez FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Tremollieres FA, Goulis DG (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. *Maturitas* 101; 23030. <https://doi.org/10.1016/j.maturitas.2017.04.008>
8. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF et al. (2010) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis:

- executive summary of recommendations. *Endocr Pract* 16: 1016-9.
<https://doi.org/10.4158/EP.16.6.1016>
9. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD et al. American Society for Bone and Mineral Research (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 25: 2267-94.
<https://doi.org/10.1002/jbmr.253>
 10. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE (2016) Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res.* 31:16-35.
<https://doi.org/10.1002/jbmr.2708>
 11. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N; et al. (2017) UK clinical guideline for the prevention and treatment of osteoporosis. *Arch Osteoporos* 12(1):43. <https://doi.org/10.1007/s11657-017-0324-5>
 12. Rabar S, Lau R, O'Flynn N, Li L, Barry P; Guideline Development Group (2012) Risk assessment of fragility fractures: summary of NICE guidance. *BMJ* 2012 Aug 8; 345:e3698 <https://doi/10.1136/bmj.e3698>
 13. Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D (2012) Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. *Osteoporos Int* 23(6):1769-1778.
<https://doi.org/10.1007/s00198-011-1793-9>
 14. Black DM, Boonen S, Cauley JA, Cummings SR, Lippuner K, Leung PC, Martinez RLM, Ruzycky ME, Eastell R (2012a) Erratum: The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the horizon-pivotal fracture trial (PFT). *J Bone Miner Res* 27(12):2612.
<https://doi.org/10.1002/jbmr.1494>
 15. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings

- SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzycky ME, Su G, Eastell R (2012b) The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res* 27(2):243-254. <https://doi.org/10.1002/jbmr.1494>
16. Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftiring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-pivotal fracture trial (PFT). *J Bone Miner Res* 30(5): 934-944. <https://doi.org/10.1002/jbmr.2442>
 17. Bone HG, Bolognese MA, Yuenn CK, Kendler DL, Miller PD, Yang YC, Grazette L, Martin JS, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. *J Clin Endocrinol Metab* 96(4):972-980. <https://doi.org/10.1210/jc.2010-1502>
 18. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellstrom D, Radominski SC, Reginster JY, Resch H, Roman Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. *J Clin Endocrinol Metab* 98(11):4483-4492. <https://doi.org/10.1210/jc.2013-1597>
 19. Borah B, Dufresne T, Nurre J, Phipps R, Chmielewski P, Wagner L, Lundy M, Boussein M, Zebaze R, Seeman E (2010) Risedronate reduces intracortical porosity in women with osteoporosis. *J Bone Miner Res* 25(1):41-47. <https://doi.org/10.1359/jbmr.090711>
 20. Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Jensen JEB, Bolognese MA, Daizadeh N, Valter I, Zerbini CAF, Dempster DW (2014) Effects of Up to 5 years of denosumab treatment on bone histology and histomorphometry: The FREEDOM study extension. *J Bone Miner Res* 29(9):2051-2056. <https://doi.org/10.1002/jbmr.2236>
 21. Brown JP, Roux C, Topping O, Ho PR, Beck Jensen JE, Gilchrist N, Recknor C, Austin

- M, Wang A, Grauer A, Wagman RB (2013) Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. *J Bone Miner Res* 28(4):746-752. <https://doi.org/10.1002/jbmr.1808>
22. Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, Cummings SR, Black DM (2014) Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: When is it reasonable to discontinue treatment? *J Clin Endocrinol Metab* 99(12):4546-4554. <https://doi.org/10.1210/jc.2014-1971>
 23. Eastell R, Boonen S, Cosman F, Reid IR, Palermo L, Cummings SR, Black DM (2015) Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study. *J Bone Miner Res* 30(3):483-487. <https://doi.org/10.1002/jbmr.2361>
 24. Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A (2011) Effect of stopping risedronate after long-term treatment on bone turnover. *J Clin Endocrinol Metab* 96(11):3367-3373. <https://doi.org/10.1210/jc.2011-0412>
 25. Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY, Torring O, Kendler DL, Daizadeh NS, Wang A, O'Malley CD, Wagman RB, Libanati C, Lewiecki EM (2015) Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. *Osteoporos Int* 26(12):2763-2771. <https://doi.org/10.1007/s00198-015-3179-x>
 26. Hassler N, Gamsjaeger S, Hofstetter B, Brozek W, Klaushofer K, Paschalis EP (2015) Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties. *Osteoporos Int* 26(1):339-352. <https://doi.org/10.1007/s00198-014-2929-5>
 27. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SAM (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. *Lancet* 386(9999):1147-1155. [https://doi.org/10.1016/S0140-6736\(15\)61120-5](https://doi.org/10.1016/S0140-6736(15)61120-5)
 28. McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, Ding B, Rockabrand E, Wagman RB, Miller PD (2013) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a

- phase 2 clinical trial. *Osteoporos Int* 24(1):227-235.
<https://doi.org/10.1007/s00198-012-2052-4>
29. McNabb B, Vittinghoff E, Eastell R, Schwartz AV, Bauer DC, Ensrud K, Barrett-Connor E, Black DM (2014) A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. *J Clin Endocrinol Metab* 99(11):4094-4100. <https://doi.org/10.1210/jc.2014-1193>
 30. McNabb BL, Vittinghoff E, Schwartz AV, Eastell R, Bauer DC, Ensrud K, Rosenberg E, Santora A, Barrett-Connor E, Black DM (2013) BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. *J Bone Miner Res* 28(6):1319-1327.
<https://doi.org/10.1002/jbmr.1864>
 31. Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanaukaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P (2012) Efficacy of monthly oral ibandronate is sustained over 5 years: The MOBILE long-term extension study. *Osteoporos Int* 23(6):1747-1756. <https://doi.org/10.1007/s00198-011-1773-0>
 32. Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: Six-year results of a phase 2 clinical trial. *J Clin Endocrinol Metab* 96(2):394-402.
<https://doi.org/10.1210/jc.2010-1805>
 33. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Man Z, Mellstrom D, Radominski SC, Reginster JY, Resch H, Ivorra JAR, Roux C, Vittinghoff E, Austin M, Daizadeh N, Bradley MN, Grauer A, Cummings SR, Bone HG (2012) Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. *J Bone Miner Res* 27(3):694-701. <https://doi.org/10.1002/jbmr.1479>
 34. Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM, Brandi ML, Czerwinski E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. *Osteoporos Int* 26(12):2773-2783. <https://doi.org/10.1007/s00198-015-3234-7>

35. Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, Moffett A, Siddhanti S, Ferreira I, Ghelani P, Wagman RB, Hall JW, Bolognese MA, Benhamou CL (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. *Obstet Gynecol* 121(6):1291-1299. <https://doi.org/10.1097/AOG.0b013e318291718c>
36. Roschger P, Lombardi A, Misof BM, Maier G, Fratzl-Zelman N, Fratzl P, Klaushofer K (2010) Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX). *J Bone Miner Res* 25(1):48-55. <https://doi.org/10.1359/jbmr.090702>
37. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, et al. (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. *J Bone Miner Res* 19(8):1259-69. <https://doi.org/10.1359/JBMR.040326>
38. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR, et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *JAMA* 296(24):2927-38. <https://doi.org/10.1001/jama.296.24.2927>
39. Tsoardi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gueñabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. *Bone* 105:11-7. <https://doi.org/10.1016/j.bone.2017.08.003>
40. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Torring O, Valter I, Wang AT, Brown JP (2017) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. *J Bone Miner Res* 33(2):190-8. <https://doi.org/10.1002/jbmr.3359>

41. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. *J Bone Miner Res* 32(6):1291-6. <https://doi.org/10.1002/jbmr.3110>
42. McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. *Osteoporos Int* 28(5): 1723-32. <https://doi.org/10.1007/s00198-017-3919-1>
43. Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K (2018) Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis. *Calcif Tissue Int* 103(1):50-4. <https://doi.org/10.1007/s00223-018-0394-4>
44. Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR (2018) Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. *Osteoporos Int* 29(1):41-7. <https://doi.org/10.1007/s00198-017-4242-6>
45. Brown JP, Roux C, Törring O, Ho PR, Beck Jensen JE, Gilchrist N, Recknor C, Austin M, Wang A, Grauer A, Wagman RB (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. *J Bone Miner Res*. 28(4):746-52. <https://doi.org/10.1002/jbmr.1808>
46. Adachi JD, Bone HG, Daizadeh NS, Dakin P, Papapoulos S, Hadji P, Recknor C, Bolognese MA, wang A, Lin CJF, Wagman RB, Ferrari S (2017) Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM extension study. *BMC Musculoskelet Disord* 18:174. <https://doi.org/10.1186/s12891-017-1520-6>
47. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. *Lancet Diabetes Endocrinol* 2017 5(7):513-23. [https://doi.org/10.1016/S2213-8587\(17\)30138-9](https://doi.org/10.1016/S2213-8587(17)30138-9)

48. Schwarz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM; FLEX Research Group (2010) Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. *J Bone Miner Res* 25(5):976-82. <https://doi.org/10.1002/jbmr.11>
49. Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, Cummings SR, Black DM (2014) Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. *JAMA Intern Med* 174(7):1126-34. <https://doi.org/10.1001/jamainternmed.2014.1232>
50. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Törring O, Valter I, Wang AT, Brown JP (2018) Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. *J Bone Miner Res* 33(2):190-8. <https://doi.org/10.1002/jbmr.3337>
51. Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R (2018) Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. *Osteoporos Int*. 29(6):1407-1417. <https://doi.org/10.1007/s00198-018-4460-6>
52. Strom O, Landfeldt E, Garellick G (2015) Residual effect after oral bisphosphonate treatment and healthy adhere effects – the Swedish Adherence Register Analysis (SARA). *Osteoporos Int* 26(1):315-25. <https://doi.org/10.1007/s00198-014-2900-5>
53. Xu LH, Adams-Huet B, Poindexter JR, Maalouf NM (2016) Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. *Osteoporosis Int* 27(5):1701-8. <https://doi.org/10.1007/s00198-015-3447-9>
54. Mignot MA, Taisne N, Legroux I, Cortet B, Paccou (2017) Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. *Osteoporosis Int* 28:3431-8. <https://doi.org/10.1007/s00198-017-4215-9>
55. Curtis JR, Westfall AO, Cheng H, Delzell E, Saag KG (2008) Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. *Osteoporosis Int* 19:1613-20. <https://doi.org/10.1007/s00198-008-0604-4>
56. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC, et al. (2010) Bisphosphonates

- and fractures of the subtrochanteric or diaphyseal femur. *N Engl J Med* 362(19):1761-71. <https://doi.org/10.1056/NEJMoa1001086>
57. Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. *N Engl J Med* 364(18):1728-37. <https://doi.org/10.1056/NEJMoa1010650>
 58. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K (2015) Risk of femoral fracture during and after bisphosphonate therapy. *Acta Orthop.* 2015 Feb;86(1):100-7. <https://doi.org/10.3109/17453674.2015.1004149>.
 59. Adams AL, Li BH, Ryan DS, Geiger EJ, Dell RM, Black DM. Do drug holidays reduce atypical femur fracture risk?: results from the Southern California Osteoporosis Cohort Study (SOCS). Abstract 1005 presented at the ASBMR meeting 2018
 60. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisman EO, Zhou H, Burchetter RJ, Ott SM (2012). Incidence of atypical nontraumatic diaphyseal fractures of the femur. *J Bone Miner Res* 27(12):2544-50. <https://doi.org/10.1002/jbmr.1719>
 61. Khaw KS, Shibu P, Yu SC, Chehade MJ, Visvanathan R (2017) Epidemiology and Postoperative Outcomes of Atypical Femoral Fractures in Older Adults: A Systematic Review. *J Nutr Health Aging* 21(1):83-91. <https://doi.org/10.1007/s12603-015-0652-3>
 62. Kharazmi M, Hallberg P, Schilcher J, Aspenberg P, Michaëlsson K (2016) Mortality after hip fracture. *J Bone Miner Res.* 2016 Mar;31(3):491-7. <https://doi.org/10.1002/jbmr.2767>.
 63. Marx RE (2003) Pamidronate and zoledronate induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg* 61(9):1115-7. [https://doi.org/10.1016/S0278-2391\(03\)00720-1](https://doi.org/10.1016/S0278-2391(03)00720-1)
 64. Lo JC, O'Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. *J Oral Maxillofac Surg* 68(2):243–53. <https://doi.org/10.1016/j.joms.2009.03.050>
 65. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B,

- Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J, et al. (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res* 30(1):3-23. <https://doi.org/10.1002/jbmr.2405>
66. Woo SB, Hellstein JW, Kalmar JR. Systematic Review: Bisphosphonates and osteonecrosis of the jaws (2006) *Ann Intern Med* 144(10):753-61. <https://doi.org/10.7326/0003-4819-144-10-200605160-00009>
 67. Marx RE, Sawatari Y, Fortin M, Bromand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. *J Oral Maxillofac Surg* 63(11):1567-75. <https://doi.org/10.1016/j.joms.2005.07.010>
 68. Masoodi N (2009) Oral bisphosphonates and the risk for osteonecrosis of the jaw. *BJMP* 2(2):11-5.
 69. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med* 356(18):1809-22. <https://doi.org/10.1056/NEJMoa067312>
 70. Choi WS, Lee JI, Yoon HJ, Min CK, Lee SH (2017) Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma. *Maxillofac Plast Reconstr Surg* 39(1):1. <https://doi.org/10.1186/s40902-016-0099-4>
 71. Eiken PA, Prieto-Alhambra D, Eastell R, Abrahamsen B (2017) Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. *Osteoporosis Int* 28(10):2921–8. <https://doi.org/10.1007/s00198-017-4132-y>
 72. Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R (2016) Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of

- alendronate: Nationwide cohort and nested case-control study. *BMJ* 2016;353:i3365. <https://doi.org/10.1136/bmj.i3365>
73. Bae SJ, Lee SH, Ahn SH, Kim HM, Kim BJ, Koh JM (2016) The circulating sphingosine-1-phosphate level predicts incident fracture in postmenopausal women: a 3.5-year follow-up observation study. *Osteoporos Int* 27(8):2533-41. <https://doi.org/10.1007/s00198-016-3565-z>
 74. Morales-Santana S, Diez-Perez A, Olmos JM, Nogues X, Sosa M, Diaz-Curiel M, Perez-Castrillon JL, Perez-Cano R, Torrijos A, Jodar E, Rio LD, Caeiro-Rey JR, Reyes-Garcia R, Garcia-Fontana B, Gonzalez-Macias J, Munoz-Torres M (2015) Circulating sclerostin and estradiol levels are associated with inadequate response to bisphosphonates in postmenopausal women with osteoporosis. *Maturitas* 82(4):402-410. <https://doi.org/10.1016/j.maturitas.2015.08.007>
 75. Shiraki M, Kuroda T, Shiraki Y, Tanaka S, Higuchi T, Saito M (2011) Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment. *J Bone Miner Metab* 29(1):62-70. <https://doi.org/10.1007/s00774-010-0191-2>
 76. Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I (2014). Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. *Osteoporos Int* 25(4):1401-10. <https://doi.org/10.1007/s00198-014-2619-3>
 77. Adams AL, Adams JL, Raebel MA, Tang BT, Kuntz JL, Vijayadeva V, McGlynn EA, Gozansky WS (2018) Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study. *J Bone Miner Res* 33(7):1252-9. <https://doi.org/10.1002/jbmr.3420>
 78. Curtis J, Chen R, Li Z, Arora T, Saag K, Wright N, Daigle S, Kilgore M, Delzell E. The impact of bisphosphonate drug holidays on fracture rates. Abstract 1006 presented at the ASBMR meeting 2018
 79. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, X Zhao, A Grauer (2008). Fracture risk remains reduced one year after discontinuation of risedronate. *Osteoporosis Int* 19(3): 365-372

Table 1 Key findings of available RCT data

Medication	Study	Outcomes recorded	Key findings	Reference
Alendronate	FLEX	BMD; fracture	2-2.5% difference in BMD in groups receiving 5 or 8 years therapy; clinical vertebral fractures higher in 5 year group	37,38
Risedronate	VERT	BTM; BMD	Difference between 2 and 7 years therapy	24
Risedronate	VERT-NA	BTM; BMD; fracture	One year after discontinuation of 3 year's treatment with risedronate, BMD decreased at the lumbar spine and hip and BTM returned to control group levels. Risk of new morphometric vertebral fractures remained lower in previous risedronate patients vs previous control patients.	79
Zoledronate	HORIZON (6 vs 3 years therapy)	BTM; BMD; fracture	In participants receiving 3 years vs 6 years therapy, differences seen in BTM (start to return to normal but remain below baseline in 3 year group); FN BMD trended downwards in 3 year group; morphometric vertebral fracture higher in 3 year group	14
Zoledronate	HORIZON (9 vs 6 year therapy)	BTM; BMD; fracture	Small non-significant differences in BTM, BMD and fracture between the two groups	16
Ibandronate		BTM; BMD	Discontinuation of 3 BiPs (Alendronate, risedronate, ibandronate) all resulted in reduction in hip BMD and rise in BTM	51
Denosumab	FREEDOM	BMD; vertebral fracture	10 year treatment associated with lower vertebral and non-vertebral fracture rates than virtual placebo cohort; if not followed by BiP therapy, denosumab withdrawal associated with bone loss and vertebral fracture	39-46

BTM bone turnover marker

BMD bone mineral density

BiP bisphosphonate

Table 2 Summary of risk of atypical femoral fracture in BiP users, relative to placebo from an analysis by Black et al [56]

Study population (drug used vs placebo)	Study	Relative hazard atypical fracture in active treated group, with 95% CI
Alendronate	FIT	1.03 (0.06-16.46)
Zoledronate	HORIZON	1.50 (0.25-9)
Alendronate	FLEX	1.33 (0.12-14.67)

Participants - Post-menopausal women on osteoporosis medication for ≥ 1 years;
Intervention - denosumab, or bisphosphonates
Comparison - Medication continuation vs discontinuation.
Outcomes - Bone turnover markers; bone mineral density (BMD); fracture; osteonecrosis of the jaw; atypical femoral fracture.




Figure 1 Overview of studies reporting the findings of randomised controlled trials included